KZR
NASDAQ · Biotechnology
Kezar Life Sciences Inc
$7.29
-0.07 (-0.95%)
Open$7.36
Previous Close$7.36
Day High$7.47
Day Low$7.27
52W High$7.55
52W Low$5.98
Volume—
Avg Volume131.6K
Market Cap53.86M
P/E Ratio—
EPS$-7.66
SectorBiotechnology
Analyst Ratings
Hold
9 analysts
Price Target
+158.0% upside
Current
$7.29
$7.29
Target
$18.81
$18.81
$12.87
$18.81 avg
$22.25
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.79M | 17.27M | 15.12M |
| Net Income | 1.29M | 1.30M | 1.12M |
| Profit Margin | 7.7% | 7.5% | 7.4% |
| EBITDA | 2.04M | 2.03M | 1.93M |
| Free Cash Flow | 959.0K | 942.1K | 1.29M |
| Rev Growth | +17.9% | +7.1% | +16.0% |
| Debt/Equity | 0.82 | 0.90 | 0.98 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $465.12 | -0.42% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $168.34 | +0.23% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $538.08 | -0.84% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $955.02 | +0.40% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $164.26 | +4.86% | 7.7 | 20.98B |